1. Home
  2. AEON vs KTTA Comparison

AEON vs KTTA Comparison

Compare AEON & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

HOLD

Current Price

$0.40

Market Cap

19.0M

Sector

Health Care

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.49

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEON
KTTA
Founded
N/A
2020
Country
United States
United States
Employees
8
5
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0M
18.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AEON
KTTA
Price
$0.40
$0.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$7.20
$3.00
AVG Volume (30 Days)
50.8K
598.6K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.28
52 Week High
$1.45
$2.06

Technical Indicators

Market Signals
Indicator
AEON
KTTA
Relative Strength Index (RSI) 18.98 32.53
Support Level N/A $0.28
Resistance Level $0.75 $0.86
Average True Range (ATR) 0.05 0.06
MACD -0.03 0.00
Stochastic Oscillator 0.74 7.14

Price Performance

Historical Comparison
AEON
KTTA

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: